Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK3 V718L |
| Therapy | Quizartinib |
| Indication/Tumor Type | esophagus adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK3 V718L | esophagus adenocarcinoma | sensitive | Quizartinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) inhibited viability of cells derived from the brain metastases of a patient with esophagus adenocarcinoma harboring JAK3 V718L in culture (PMID: 38985431). | 38985431 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38985431) | A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases. | Full reference... |